NCT04653246: Phase 2: Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

• NCT04653246: Phase 2: Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.

Sponsor

Jacob Laubach

Collaborator

Sanofi

---

ClinicalTrials.gov Identifier: NCT04653246

Official Title: Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

First Posted : December 4, 2020

Click here to see details on ClinicalTrials.gov

---

Dexamethasone : National Cancer Institute

Isatuximab : National Cancer Institute

Lenalidomide: National Cancer Institute

Bortezomib : National Cancer Institute

---

Drug: Isatuximab

Drug: Lenalidomide

Drug: Bortezomib Injection

Drug: Dexamethasone

---

Location

United States, Massachusetts